How to screen and diagnose deep venous thrombosis (DVT) in patients hospitalized for or suspected of COVID-19 infection, outside the intensive care units.


Journal

Journal de medecine vasculaire
ISSN: 2542-4513
Titre abrégé: J Med Vasc
Pays: France
ID NLM: 101709200

Informations de publication

Date de publication:
Dec 2020
Historique:
received: 10 08 2020
accepted: 26 08 2020
entrez: 29 11 2020
pubmed: 30 11 2020
medline: 15 12 2020
Statut: ppublish

Résumé

The Coronavirus disease-2019 outbreak (COVID-19) has been declared a pandemic by the World Health Organization. Studies report both a severe inflammatory syndrome and a procoagulant state in severe COVID-19 cases, with an increase of venous thromboembolism, including pulmonary embolism (PE) and deep vein thrombosis (DVT). In this context, we discuss the use of doppler ultrasonography (DUS) in the screening and diagnosis of DVT in ambulatory and hospitalized patients with, or suspected of having, COVID-19, outside the intensive care unit (ICU). Non-systematic review of the literature. In patients hospitalized for or suspected of COVID-19 infection with the presence of either (a) DVT clinical symptoms, (b) a strong DVT clinical probability (Wells score>2) or (c) elevated D-dimer levels without DVT clinical symptoms and without PE on lung CT angio-scan, DVT should be investigated with DUS. In the presence of PE diagnosed clinically and/or radiologically, additional systematic DVT screening using DUS is not recommended during the COVID-19 pandemic. The use of 4-points compression DUS for DVT screen and diagnosis is the most appropriate method in this context. Systematic DUS for DVT screening in asymptomatic COVID patients is not recommended unless the patient is in the ICU. This would increase the risk of unnecessarily exposing medical staff to SARS-CoV-2 and monopolizing limited resources during this period.

Identifiants

pubmed: 33248536
pii: S2542-4513(20)30338-2
doi: 10.1016/j.jdmv.2020.08.002
pmc: PMC7473249
pii:
doi:

Substances chimiques

Biomarkers 0
Fibrin Fibrinogen Degradation Products 0
fibrin fragment D 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

334-343

Informations de copyright

Copyright © 2020 Elsevier Masson SAS. All rights reserved.

Références

Intensive Care Med. 2020 Jun;46(6):1089-1098
pubmed: 32367170
Thromb Res. 2020 Jul;191:145-147
pubmed: 32291094
Emerg Infect Dis. 2020 Jul;26(7):1583-1591
pubmed: 32275497
Emerg Infect Dis. 2020 Jul;26(7):1470-1477
pubmed: 32255761
Arch Iran Med. 2020 Apr 01;23(4):268-271
pubmed: 32271601
Thromb Haemost. 2020 Jun;120(6):998-1000
pubmed: 32316063
Ann Intensive Care. 2019 Jan 30;9(1):19
pubmed: 30701381
Thromb Res. 2020 Aug;192:23-26
pubmed: 32405101
N Engl J Med. 2003 Sep 25;349(13):1227-35
pubmed: 14507948
BMC Med Imaging. 2005 Oct 03;5:6
pubmed: 16202135
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Lancet Oncol. 2019 Oct;20(10):e566-e581
pubmed: 31492632
Blood. 2019 Feb 28;133(9):906-918
pubmed: 30642917
Thromb Haemost. 2020 May;120(5):876-878
pubmed: 32246450
JAMA. 2014 Mar 19;311(11):1117-24
pubmed: 24643601
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Eur Heart J. 2020 Jan 21;41(4):543-603
pubmed: 31504429
J Thromb Haemost. 2020 Jun;18(6):1421-1424
pubmed: 32271988
J Allergy Clin Immunol. 2020 Jul;146(1):110-118
pubmed: 32294485
J Thromb Haemost. 2020 Jul;18(7):1743-1746
pubmed: 32320517
Ann Emerg Med. 2010 Dec;56(6):601-10
pubmed: 20864215
BMJ. 1998 Jan 3;316(7124):17-20
pubmed: 9451260
J Thromb Thrombolysis. 2020 Jul;50(1):211-216
pubmed: 32451823
J Thromb Haemost. 2020 Jul;18(7):1747-1751
pubmed: 32302448
Eur Heart J. 2020 May 14;41(19):1858
pubmed: 32227120
Thromb Res. 2020 Jul;191:148-150
pubmed: 32381264
Science. 2020 Apr 10;368(6487):119
pubmed: 32273447
JAMA Oncol. 2020 May 1;6(5):631-632
pubmed: 32236504
J Thromb Haemost. 2020 Apr;18(4):844-847
pubmed: 32073213
Crit Care Med. 2015 Feb;43(2):401-10
pubmed: 25474533
J Med Vasc. 2020 Jul;45(4):210-213
pubmed: 32571561
Ann Emerg Med. 2017 May;69(5):e27-e54
pubmed: 28442101
Ann Emerg Med. 2008 Oct;52(4):437-45
pubmed: 18562044
Intensive Care Med. 2020 Apr;46(4):586-590
pubmed: 32125455
Thromb Res. 2019 Sep;181:77-83
pubmed: 31376606
Blood. 2020 Jun 4;135(23):2033-2040
pubmed: 32339221
Radiology. 2020 Sep;296(3):E186-E188
pubmed: 32324103
Eur Radiol. 2020 Sep;30(9):4903-4909
pubmed: 32314058
Circulation. 2020 Jul 14;142(2):114-128
pubmed: 32421381
J Am Coll Cardiol. 2020 Jul 28;76(4):480-482
pubmed: 32479784
Thromb Res. 2020 Jul;191:76-77
pubmed: 32402996
J Thromb Thrombolysis. 2020 Jun 30;:
pubmed: 32607652
Lancet. 1997 Dec 20-27;350(9094):1795-8
pubmed: 9428249
Thromb Res. 2020 Jul;191:9-14
pubmed: 32353746
Radiology. 2020 Sep;296(3):E189-E191
pubmed: 32324102
Thromb Res. 2017 Jan;149:38-44
pubmed: 27886531
N Engl J Med. 2003 Sep 25;349(13):1203-4
pubmed: 14507947
J Thromb Haemost. 2020 Aug;18(8):1995-2002
pubmed: 32369666
J Med Vasc. 2019 Feb;44(1):e1-e47
pubmed: 30770089
JAMA. 2020 May 12;323(18):1775-1776
pubmed: 32203977
J Thromb Haemost. 2020 Jul 6;:
pubmed: 32633068
Eur Heart J. 2008 Sep;29(18):2276-315
pubmed: 18757870
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Eur Rev Med Pharmacol Sci. 2020 Mar;24(5):2776-2780
pubmed: 32196627
Chest. 2020 Sep;158(3):1143-1163
pubmed: 32502594
Arterioscler Thromb Vasc Biol. 2003 Jan 1;23(1):17-25
pubmed: 12524220
Crit Care. 2020 Jun 18;24(1):360
pubmed: 32552865
J Am Coll Cardiol. 2020 Jun 16;75(23):2950-2973
pubmed: 32311448
J Thromb Haemost. 2020 Aug;18(8):1859-1865
pubmed: 32459046
Obesity (Silver Spring). 2020 Jul;28(7):1195-1199
pubmed: 32271993
J Thromb Haemost. 2020 May;18(5):1094-1099
pubmed: 32220112
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
Rev Mal Respir. 2019 Jul 4;:
pubmed: 31280989
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
J Exp Med. 2020 Jun 1;217(6):
pubmed: 32302401
Circulation. 2020 Jul 14;142(2):184-186
pubmed: 32330083
Circulation. 2020 Aug 11;142(6):611-614
pubmed: 32776849
Intensive Care Med. 2020 Aug;46(8):1603-1606
pubmed: 32415314

Auteurs

M Sebuhyan (M)

Unité de médecine interne : maladies auto-immunes et pathologie vasculaire (UF04), hôpital Saint-Louis, Assistance publique-Hôpitaux de Paris (AP-HP), 1, avenue Claude-Vellefaux, 75010 Paris, France. Electronic address: maxime.sebuhyan@aphp.fr.

R Mirailles (R)

Unité de médecine interne : maladies auto-immunes et pathologie vasculaire (UF04), hôpital Saint-Louis, Assistance publique-Hôpitaux de Paris (AP-HP), 1, avenue Claude-Vellefaux, 75010 Paris, France.

B Crichi (B)

Unité de médecine interne : maladies auto-immunes et pathologie vasculaire (UF04), hôpital Saint-Louis, Assistance publique-Hôpitaux de Paris (AP-HP), 1, avenue Claude-Vellefaux, 75010 Paris, France.

C Frere (C)

Inserm UMRS_1166, service d'hématologie biologique, Sorbonne université, hôpital Pitié-Salpêtrière, Assistance publique-Hôpitaux de Paris (AP-HP), 47-83, boulevard de l'Hôpital, 75013 Paris, France.

P Bonnin (P)

Service de physiologie clinique et explorations fonctionnelles, hôpital Lariboisière, Assistance publique-Hôpitaux de Paris (AP-HP), Paris, France.

A Bergeron-Lafaurie (A)

Service de pneumologie, hôpital Saint-Louis, Assistance publique-hôpitaux de Paris (AP-HP), 1, avenue Claude-Vellefaux, 75010 Paris, France.

B Denis (B)

Service de maladie infectieuse, hôpital Saint-Louis, Assistance publique-Hôpitaux de Paris (AP-HP), 1, avenue Claude-Vellefaux, 75010 Paris, France.

G Liegeon (G)

Service de maladie infectieuse, hôpital Saint-Louis, Assistance publique-Hôpitaux de Paris (AP-HP), 1, avenue Claude-Vellefaux, 75010 Paris, France.

O Peyrony (O)

Service des urgences, hôpital Saint-Louis, Assistance publique-Hôpitaux de Paris (AP-HP), 1, avenue Claude-Vellefaux, 75010 Paris, France.

D Farge (D)

Unité de médecine interne : maladies auto-immunes et pathologie vasculaire (UF04), hôpital Saint-Louis, Assistance publique-Hôpitaux de Paris (AP-HP), 1, avenue Claude-Vellefaux, 75010 Paris, France; IRSL, EA-3518, recherche clinique appliquée à l'hématologie, université de Paris, 75010 Paris, France; Department of medicine, McGill university, Montreal, QC, Canada. Electronic address: dominique.farge-bancel@aphp.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH